EARN25

2 Sleep Apnea Stocks in Focus Today

The FDA approved Eli Lilly's weight-loss drug for sleep apnea

Deputy Editor
Dec 23, 2024 at 10:51 AM
facebook X logo linkedin


Eli Lilly and Co (NYSE:LLY) is in focus today, after the U.S. Food & Drug Administration (FDA) approved its weight-loss drug, Zepbound, to treat obstructive sleep apnea in adults with obesity -- the first such treatment in the country. LLY is up 1.7% at $480.55 at last glance, while shares of rival ResMed Inc (NYSE:RMD), which creates continuous positive airway pressure (CPAP) devices for sleep apnea, was last seen down 5% at $225.44 after the news. 

On the charts, LLY posted a much-needed rebound last session, marking its second gain in 10 trading days after bouncing off the 320-day moving average. This came amid Novo Nordisk (NVO) stock's plummet after the pharma name's weight-loss drug CagriSema missed expectations of a late-stage study. Eli Lilly stock has been volatile since its late-October bear gap, which it has yet to recover from, up 33.2% since the start of the year. 

RMD is trading at its lowest levels since late August, though the 180-day moving average, which captured its June pullback, lingers below as potential support. The shares are further removing themselves from their Oct. 25 two-year high of $260.49. Year to date, the equity is up 30.9%. 

 

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!